

Bo Abrahamsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3702981/publications.pdf>

Version: 2024-02-01

264
papers

14,615
citations

22099

59
h-index

24179

110
g-index

276
all docs

276
docs citations

276
times ranked

12489
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1-23.	3.1	1,424
2	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2267-2294.	3.1	994
3	Excess mortality following hip fracture: a systematic epidemiological review. <i>Osteoporosis International</i> , 2009, 20, 1633-1650.	1.3	805
4	Mechanisms of diabetes mellitus-induced bone fragility. <i>Nature Reviews Endocrinology</i> , 2017, 13, 208-219.	4.3	678
5	Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. <i>Age and Ageing</i> , 2010, 39, 203-209.	0.7	428
6	Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. <i>BMJ: British Medical Journal</i> , 2010, 340, b5463-b5463.	2.4	342
7	Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1095-1102.	3.1	316
8	Diagnosis and management of bone fragility in diabetes: an emerging challenge. <i>Osteoporosis International</i> , 2018, 29, 2585-2596.	1.3	237
9	Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2670-2681.	1.8	186
10	A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3161-3169.	1.8	179
11	Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. <i>Bone</i> , 1995, 16, 385-390.	1.4	154
12	Risk assessment tools to identify women with increased risk of osteoporotic fracture: Complexity or simplicity? A systematic review. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1701-1717.	3.1	150
13	Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5258-5265.	1.8	147
14	Antidepressant medications and osteoporosis. <i>Bone</i> , 2012, 51, 606-613.	1.4	144
15	Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3848-3857.	1.8	144
16	Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women – results of the Danish Osteoporosis Prevention Study. <i>Maturitas</i> , 2000, 36, 181-193.	1.0	139
17	Adverse Effects of Bisphosphonates. <i>Calcified Tissue International</i> , 2010, 86, 421-435.	1.5	139
18	Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006. <i>Osteoporosis International</i> , 2010, 21, 373-380.	1.3	137

#	ARTICLE	IF	CITATIONS
19	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , 2019, 40, 333-368.	8.9	136
20	Safety of bisphosphonates. <i>Bone</i> , 2011, 49, 103-110.	1.4	135
21	Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. <i>Cardiovascular Diabetology</i> , 2018, 17, 37.	2.7	133
22	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281.	1.8	132
23	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. <i>Osteoporosis International</i> , 2017, 28, 2023-2034.	1.3	126
24	Safety issues with bisphosphonate therapy for osteoporosis. <i>Rheumatology</i> , 2014, 53, 19-31.	0.9	122
25	Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 172, 627-638.	1.9	115
26	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. <i>Osteoporosis International</i> , 2017, 28, 767-774.	1.3	113
27	Risks and Benefits of Bisphosphonate Therapies. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 20-28.	1.2	108
28	A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1335-1342.	1.8	105
29	Atrial fibrillation in fracture patients treated with oral bisphosphonates. <i>Journal of Internal Medicine</i> , 2009, 265, 581-592.	2.7	102
30	Hormone Replacement Therapy Dissociates Fat Mass and Bone Mass, and Tends to Reduce Weight Gain in Early Postmenopausal Women: A Randomized Controlled 5-Year Clinical Trial of the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 333-342.	3.1	99
31	Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study. <i>Thyroid</i> , 2018, 28, 566-574.	2.4	98
32	Correlations between insulin sensitivity and bone mineral density in non-diabetic men. <i>Diabetic Medicine</i> , 2000, 17, 124-129.	1.2	97
33	Low Serum Thyrotropin Level and Duration of Suppression as a Predictor of Major Osteoporotic Fractures—The OPENTHYRO Register Cohort. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2040-2050.	3.1	96
34	A Common Methylene-tetrahydrofolate Reductase (C677T) Polymorphism Is Associated With Low Bone Mineral Density and Increased Fracture Incidence After Menopause: Longitudinal Data From the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 723-729.	3.1	92
35	Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 555-567.	0.7	92
36	Impact of hemodialysis on dual X-ray absorptiometry, bioelectrical impedance measurements, and anthropometry. <i>American Journal of Clinical Nutrition</i> , 1996, 63, 80-86.	2.2	91

#	ARTICLE	IF	CITATIONS
37	Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. <i>Bone</i> , 2013, 56, 16-22.	1.4	91
38	Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 125-134.	3.1	89
39	Cytokines and Bone Loss in a 5-Year Longitudinal Study-Hormone Replacement Therapy Suppresses Serum Soluble Interleukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 1545-1554.	3.1	88
40	Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 2159-2166.	3.1	84
41	More on Reports of Esophageal Cancer with Oral Bisphosphonate Use. <i>New England Journal of Medicine</i> , 2009, 360, 1789-1792.	13.9	79
42	Vitamin D insufficiency is associated with increased risk of first-trimester miscarriage in the Odense Child Cohort. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 633-638.	2.2	78
43	Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2301-2309.	1.8	78
44	Side effects of drugs for osteoporosis and metastatic bone disease. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1063-1071.	1.1	78
45	Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study. <i>Osteoporosis International</i> , 2012, 23, 2693-2701.	1.3	77
46	Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate. <i>Archives of Internal Medicine</i> , 2011, 171, 998-1004.	4.3	76
47	Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. <i>Thyroid</i> , 2019, 29, 332-340.	2.4	74
48	Fracture risk in Danish men with prostate cancer: a nationwide register study. <i>BJU International</i> , 2007, 100, 749-754.	1.3	73
49	Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. <i>BMJ, The</i> , 2016, 353, i3365.	3.0	73
50	Site of Osteodensitometry in Perimenopausal Women: Correlation and Limits of Agreement Between Anatomic Regions. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1471-1479.	3.1	72
51	Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. <i>Osteoporosis International</i> , 2009, 20, 299-307.	1.3	71
52	The Excess Risk of Major Osteoporotic Fractures in Hypothyroidism Is Driven by Cumulative Hyperthyroid as Opposed to Hypothyroid Time: An Observational Register-Based Time-Resolved Cohort Analysis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 898-905.	3.1	71
53	Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population-based cohort study. <i>Clinical Endocrinology</i> , 2013, 79, 333-341.	1.2	70
54	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	1.3	69

#	ARTICLE	IF	CITATIONS
55	Proton pump inhibitors and osteoporosis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 420-425.	2.0	68
56	Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. <i>Osteoporosis International</i> , 2014, 25, 757-762.	1.3	64
57	Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3205-3214.	1.8	61
58	Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: A randomized controlled study. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 33-39.	0.7	60
59	Association of a Common Allelic Polymorphism (C677T) in the Methylene Tetrahydrofolate Reductase Gene with a Reduced Risk of Osteoporotic Fractures. A Case Control Study in Danish Postmenopausal Women. <i>Calcified Tissue International</i> , 2002, 71, 386-392.	1.5	60
60	Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures. <i>Calcified Tissue International</i> , 2005, 76, 90-97.	1.5	60
61	Bisphosphonate adverse effects, lessons from large databases. <i>Current Opinion in Rheumatology</i> , 2010, 22, 404-409.	2.0	60
62	Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects. <i>Osteoporosis International</i> , 2017, 28, 139-149.	1.3	60
63	Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. <i>Osteoporosis International</i> , 2013, 24, 245-252.	1.3	59
64	Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1654-1662.	0.4	59
65	Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study. <i>Bone</i> , 2005, 36, 577-583.	1.4	57
66	Esophageal and gastric cancer incidence and mortality in alendronate users. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 679-686.	3.1	57
67	Duration of Thyroid Dysfunction Correlates with All-Cause Mortality. The OPENTHYRO Register Cohort. <i>PLoS ONE</i> , 2014, 9, e110437.	1.1	57
68	Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1405-1412.	3.1	56
69	Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. <i>Maturitas</i> , 1997, 28, 137-145.	1.0	55
70	Skeletal changes in osteoprotegerin and receptor activator of nuclear factor- κ B ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. <i>Bone</i> , 2004, 35, 256-265.	1.4	53
71	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1682-1699.	1.8	53
72	Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. <i>European Journal of Endocrinology</i> , 2019, 180, 407-416.	1.9	52

#	ARTICLE	IF	CITATIONS
73	Vitamin D status and PTH in young men: a cross-sectional study on associations with bone mineral density, body composition and glucose metabolism. <i>Clinical Endocrinology</i> , 2010, 73, 573-580.	1.2	51
74	Epidemiology of Fractures in Diabetes. <i>Calcified Tissue International</i> , 2017, 100, 109-121.	1.5	51
75	Ten-Year Absolute Risk of Osteoporotic Fractures According to BMD T Score at Menopause: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 796-800.	3.1	49
76	Polymorphisms in the CYP19 and AR Genes?Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women With or Without Hormone Replacement Therapy: The Danish Osteoporosis Prevention Study. <i>Calcified Tissue International</i> , 2003, 74, 25-34.	1.5	48
77	Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. <i>Osteoporosis International</i> , 2015, 26, 513-519.	1.3	48
78	Eliminating the need for fasting with oral administration of bisphosphonates. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 395.	0.9	47
79	Vitamin D Receptor Alleles Do Not Predict Bone Mineral Density or Bone Loss in Danish Perimenopausal Women. <i>Bone</i> , 1998, 22, 571-575.	1.4	46
80	Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 820-832.	3.1	46
81	Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. <i>BMJ: British Medical Journal</i> , 2005, 330, 818.	2.4	44
82	Discordance Between Changes in Bone Mineral Density Measured at Different Skeletal Sites in Perimenopausal Women-Implications for Assessment of Bone Loss and Response to Therapy: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1212-1219.	3.1	43
83	Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins. <i>Bone</i> , 2005, 36, 727-735.	1.4	43
84	Population-based reference values for bone mineral density in young men. <i>Osteoporosis International</i> , 2007, 18, 1507-1514.	1.3	43
85	Do calcium plus vitamin D supplements increase cardiovascular risk?. <i>BMJ: British Medical Journal</i> , 2011, 342, d2080-d2080.	2.4	43
86	A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. <i>BoneKEY Reports</i> , 2014, 3, 574.	2.7	43
87	Nutrient and food intakes in early life and risk of childhood fractures: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1182-1195.	2.2	43
88	Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded?. <i>British Journal of Radiology</i> , 1998, 71, 934-943.	1.0	42
89	Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. <i>Bone</i> , 1997, 20, 251-258.	1.4	41
90	Osteoporosis and vertebral fractures in men aged 60-74 years. <i>Age and Ageing</i> , 2012, 41, 171-177.	0.7	41

#	ARTICLE	IF	CITATIONS
91	Oral Bisphosphonate Use and Total Knee/Hip Implant Survival: Validation of Results in an External Population-Based Cohort. <i>Arthritis and Rheumatology</i> , 2014, 66, 3233-3240.	2.9	39
92	The epidemiology of fractures in Denmark in 2011. <i>Osteoporosis International</i> , 2016, 27, 2017-2025.	1.3	39
93	Fracture risk following intermission of osteoporosis therapy. <i>Osteoporosis International</i> , 2019, 30, 1733-1743.	1.3	38
94	MTHFR c.677C>T polymorphism as an independent predictor of peak bone mass in Danish men—results from the Odense Androgen Study. <i>Bone</i> , 2006, 38, 215-219.	1.4	37
95	Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2150-2158.	1.2	37
96	Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients. <i>Osteoporosis International</i> , 2016, 27, 397-404.	1.3	36
97	Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1465-E1473.	1.8	35
98	Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study. <i>Osteoporosis International</i> , 2011, 22, 1401-1409.	1.3	35
99	Proton pump inhibitor use and fracture risk — effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. <i>Bone</i> , 2013, 57, 269-271.	1.4	35
100	Diagnostic devices for osteoporosis in the general population: A systematic review. <i>Bone</i> , 2016, 92, 58-69.	1.4	35
101	Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. <i>Maturitas</i> , 2001, 40, 211-220.	1.0	34
102	A New Fracture Risk Assessment Tool (FREM) Based on Public Health Registries. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1967-1979.	3.1	34
103	Geometry of the proximal femur in relation to age and sex: a cross-sectional study in healthy adult danes. <i>Acta Radiologica</i> , 2005, 46, 514-518.	0.5	33
104	Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. <i>Osteoporosis International</i> , 2009, 20, 585-597.	1.3	33
105	Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. <i>Bone</i> , 2000, 26, 137-145.	1.4	32
106	Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism. <i>Calcified Tissue International</i> , 2003, 73, 210-216.	1.5	32
107	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1208-1214.	1.9	32
108	Anti-osteoporotic therapy in Denmark—predictors and demographics of poor refill compliance and poor persistence. <i>Osteoporosis International</i> , 2013, 24, 2079-2097.	1.3	32

#	ARTICLE	IF	CITATIONS
109	Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 455-463.	3.1	32
110	Cardiovascular disease in patients with osteogenesis imperfecta – a nationwide, register-based cohort study. <i>International Journal of Cardiology</i> , 2016, 225, 250-257.	0.8	32
111	Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 709-717.	3.1	32
112	Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients. <i>Osteoporosis International</i> , 2015, 26, 67-76.	1.3	31
113	Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. <i>Osteoporosis International</i> , 2017, 28, 2935-2944.	1.3	31
114	Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom. <i>Osteoporosis International</i> , 2020, 31, 1535-1544.	1.3	31
115	Polymorphisms in the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene Are Associated with Peak Bone Mass in Non-sedentary Men: Results from the Odense Androgen Study. <i>Calcified Tissue International</i> , 2007, 81, 421-429.	1.5	30
116	Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2019, 53, 34-39.	0.6	30
117	Two Single Nucleotide Polymorphisms in the CYP17 and COMT Genes – Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women with or without Hormone Replacement Therapy. <i>Calcified Tissue International</i> , 2004, 75, 123-132.	1.5	29
118	Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry. <i>Osteoporosis International</i> , 2005, 16, 764-772.	1.3	29
119	Women's experiences of their osteoporosis diagnosis at the time of diagnosis and 6 months later: A phenomenological hermeneutic study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2014, 9, 22438.	0.6	29
120	Real-Life and RCT Participants: Alendronate Users Versus FITs™ Trial Eligibility Criterion. <i>Calcified Tissue International</i> , 2016, 99, 243-249.	1.5	29
121	Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. <i>Osteoporosis International</i> , 2011, 22, 1493-1501.	1.3	28
122	Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs – an analysis using national health databases. <i>Osteoporosis International</i> , 2013, 24, 2639-2647.	1.3	28
123	Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. <i>Bone</i> , 2006, 39, 189-198.	1.4	27
124	Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. <i>Bone</i> , 2012, 50, 1196-1200.	1.4	27
125	Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. <i>Osteoporosis International</i> , 2017, 28, 2921-2928.	1.3	27
126	Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. <i>Bone</i> , 2019, 120, 476-481.	1.4	27

#	ARTICLE	IF	CITATIONS
127	Two Polymorphisms in the Vitamin D Receptor Gene-Association With Bone Mass and 5-Year Change in Bone Mass With or Without Hormone-Replacement Therapy in Postmenopausal Women: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1535-1544.	3.1	26
128	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1123-1129.	0.5	26
129	Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. <i>Osteoporosis International</i> , 2012, 23, 2873-2884.	1.3	25
130	The influence of early exposure to vitamin D for development of diseases later in life. <i>BMC Public Health</i> , 2013, 13, 515.	1.2	25
131	Central nervous system medications and falls risk in men aged 60-75 years: the Study on Male Osteoporosis and Aging (SOMA). <i>Age and Ageing</i> , 2013, 42, 121-124.	0.7	25
132	Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-tect study, a population-based case-cohort study. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 155-161.	2.2	24
133	Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. <i>Clinical Endocrinology</i> , 2002, 57, 273-281.	1.2	23
134	Risk factors for fracture in elderly men: a population-based prospective study. <i>Osteoporosis International</i> , 2012, 23, 521-531.	1.3	23
135	Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1553-1559.	3.1	23
136	Low Levels of Hemoglobin at Admission Are Associated With Increased 30-Day Mortality in Patients With Hip Fracture. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2016, 7, 115-120.	0.6	23
137	The calcium and vitamin D controversy. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 107-114.	1.2	23
138	Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study. <i>Osteoporosis International</i> , 2017, 28, 2573-2581.	1.3	23
139	Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. <i>Osteoporosis International</i> , 2013, 24, 321-328.	1.3	22
140	Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study. <i>Archives of Osteoporosis</i> , 2015, 10, 36.	1.0	22
141	Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1727-1734.	1.4	21
142	Changes in bone mineral density (BMD) around the cemented Exeter stem: A prospective study in 18 women with 5 years follow-up. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2008, 79, 494-498.	1.2	20
143	The bisphosphonates: risks and benefits of long term use. <i>Current Opinion in Pharmacology</i> , 2013, 13, 435-439.	1.7	20
144	Heart failure in patients treated with bisphosphonates. <i>Journal of Internal Medicine</i> , 2013, 274, 342-350.	2.7	20

#	ARTICLE	IF	CITATIONS
145	Maternal serum retinol and $\hat{1}^2$ -carotene concentrations and neonatal bone mineralization: results from the Southampton Women's Survey cohort. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 1183-1188.	2.2	20
146	Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study. <i>BMC Women's Health</i> , 2017, 17, 17.	0.8	20
147	Social inequality and fractures' secular trends in the Danish population: a case-control study. <i>Osteoporosis International</i> , 2018, 29, 2243-2250.	1.3	20
148	Effects of the Natural and Artificial Menstrual Cycle on the Production of Osteoprotegerin and the Bone Resorptive Cytokines IL-1b and IL-6. <i>Calcified Tissue International</i> , 2003, 72, 18-23.	1.5	19
149	Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency. <i>European Journal of Endocrinology</i> , 2004, 150, 671-679.	1.9	19
150	Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture' limitations and scope for fracture liaison services in prevention of hip fracture. <i>Osteoporosis International</i> , 2018, 29, 109-114.	1.3	19
151	Fractures in women with eating disorders' incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls. <i>International Journal of Eating Disorders</i> , 2020, 53, 1080-1087.	2.1	19
152	Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1188-1199.	3.1	19
153	Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients. <i>Calcified Tissue International</i> , 2017, 101, 9-16.	1.5	18
154	Epidemiology of Tumor-Induced Osteomalacia in Denmark. <i>Calcified Tissue International</i> , 2021, 109, 147-156.	1.5	18
155	Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study. <i>Endocrine Connections</i> , 2019, 8, 1405-1415.	0.8	18
156	Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study. <i>Osteoporosis International</i> , 2006, 17, 245-251.	1.3	17
157	The role of vitamin D supplementation in patients with rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2013, 9, 411-422.	3.5	17
158	Status of drug development for the prevention and treatment of osteoporosis. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 245-253.	2.5	17
159	Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3215-3225.	1.8	17
160	Newly Diagnosed Celiac Disease and Bone Health in Young Adults: A Systematic Literature Review. <i>Calcified Tissue International</i> , 2022, 110, 641-648.	1.5	17
161	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 234-244.	3.1	16
162	Proton pump inhibitors and fracture risk. The HUNT study, Norway. <i>Osteoporosis International</i> , 2020, 31, 109-118.	1.3	16

#	ARTICLE	IF	CITATIONS
163	When Should Densitometry Be Repeated in Healthy Peri- and Postmenopausal Women: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 2061-2067.	3.1	15
164	Fracture risk assessed by Fracture Risk Assessment Tool (FRAX) compared with fracture risk derived from population fracture rates. <i>Scandinavian Journal of Public Health</i> , 2011, 39, 312-318.	1.2	15
165	Atypical femur fractures: Refining the clinical picture. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 975-976.	3.1	15
166	Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016. <i>Bone</i> , 2019, 120, 94-100.	1.4	15
167	A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. <i>Endocrine</i> , 2021, 73, 509-529.	1.1	15
168	Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study. <i>Clinical Endocrinology</i> , 2007, 67, 897-903.	1.2	14
169	No Association Between Hip Geometry and Four Common Polymorphisms Associated with Fracture: The Danish Osteoporosis Prevention Study. <i>Calcified Tissue International</i> , 2009, 84, 276-285.	1.5	14
170	Effects of COL1A1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk. <i>Osteoporosis International</i> , 2011, 22, 1145-1156.	1.3	14
171	Season of Birth and the Risk of Hip Fracture in Danish Men and Women Aged 65+. <i>Frontiers in Endocrinology</i> , 2012, 3, 2.	1.5	14
172	Temporal trends in the use of antithrombotics at admission. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2016, 87, 368-373.	1.2	14
173	Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. <i>Osteoporosis International</i> , 2018, 29, 1875-1885.	1.3	14
174	Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 24-40.	3.1	14
175	Relevance of Ki-67 expression in the classification of non-Hodgkin's lymphomas: a morphometric and double-immunostaining study. <i>Histopathology</i> , 1992, 20, 13-20.	1.6	13
176	Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. <i>Bone</i> , 2020, 134, 115296.	1.4	13
177	The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. <i>Osteoporosis International</i> , 2021, 32, 1961-1971.	1.3	13
178	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. <i>Archives of Osteoporosis</i> , 2022, 17, .	1.0	13
179	Pattern of use of DXA scans in men: a cross-sectional, population-based study. <i>Osteoporosis International</i> , 2012, 23, 183-191.	1.3	12
180	Use of anti-osteoporotic drugs in central Norway after a forearm fracture. <i>Archives of Osteoporosis</i> , 2015, 10, 235.	1.0	12

#	ARTICLE	IF	CITATIONS
181	Excess mortality following hip fracture in patients with diabetes according to age: a nationwide population-based cohort study of 154,047 hip fracture patients. <i>Age and Ageing</i> , 2019, 48, 559-563.	0.7	12
182	Age at hip fracture and life expectancy in Denmark – Secular trends over two decades. <i>Bone</i> , 2020, 130, 115083.	1.4	12
183	Denosumab: A novel antiresorptive drug for osteoporosis. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, 105-114.	0.6	12
184	The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. <i>Rhinology</i> , 2017, 55, 195-201.	0.7	12
185	Validation of the Fracture Risk Evaluation Model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data. <i>Bone</i> , 2021, 147, 115934.	1.4	11
186	Prevention and treatment of osteoporosis in women. <i>Current Obstetrics & Gynaecology</i> , 2005, 15, 251-258.	0.2	10
187	Adiponectin and Peak Bone Mass in Men: A Cross-Sectional, Population-Based Study. <i>Calcified Tissue International</i> , 2010, 87, 36-43.	1.5	10
188	Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database. <i>Osteoporosis International</i> , 2013, 24, 369-372.	1.3	10
189	Socioeconomic status in Danish women with polycystic ovary syndrome: A register-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 440-450.	1.3	10
190	Pre-fracture medication use as a predictor of 30-day mortality in hip fracture patients: an analysis of 141,201 patients. <i>HIP International</i> , 2020, 30, 101-106.	0.9	10
191	Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). <i>Osteoporosis International</i> , 2022, 33, 57-66.	1.3	10
192	Validation of a 5-year risk score of hip fracture in postmenopausal women. The Danish Nurse Cohort Study. <i>Osteoporosis International</i> , 2010, 21, 2135-2142.	1.3	9
193	Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. <i>Evidence-Based Medicine</i> , 2011, 16, 168-169.	0.6	9
194	Nutrients, Diet, and Other Factors in Prenatal Life and Bone Health in Young Adults: A Systematic Review of Longitudinal Studies. <i>Nutrients</i> , 2020, 12, 2866.	1.7	9
195	Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway. <i>Osteoporosis International</i> , 2021, 32, 1395-1404.	1.3	9
196	Technology evaluation: denosumab, Amgen. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 604-10.	2.8	9
197	Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2014, 48, 350-355.	0.6	8
198	Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 278.	0.4	8

#	ARTICLE	IF	CITATIONS
199	Assessment of fracture risk in women with eating disorders: The utility of dual-energy x-ray absorptiometry (DXA)â€”Clinical cohort study. <i>International Journal of Eating Disorders</i> , 2020, 53, 595-605.	2.1	8
200	Oral Bisphosphonate Use and All-cause Mortality in Patients With Moderate-to Severe (Grade 3-5D) Chronic Kidney Disease: A Population-based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 894-900.	3.1	8
201	The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers. <i>Bone</i> , 2020, 137, 115371.	1.4	8
202	Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. <i>JBMR Plus</i> , 2021, 5, e10522.	1.3	8
203	Disentangling the Emerging Evidence around Atypical Fractures. <i>Current Rheumatology Reports</i> , 2012, 14, 212-216.	2.1	7
204	Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?. <i>Current Osteoporosis Reports</i> , 2021, 19, 182-188.	1.5	7
205	Accelerated osteoarthritis in women with polycystic ovary syndrome: a prospective nationwide registry-based cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 225.	1.6	7
206	One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. <i>Osteoporosis International</i> , 2022, 33, 123-137.	1.3	7
207	Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. <i>Thrombosis and Haemostasis</i> , 2007, 97, 234-239.	1.8	7
208	Response rates to oestrogen treatment in perimenopausal women: 5-year data from The Danish Osteoporosis Prevention Study (DOPS). <i>Maturitas</i> , 2004, 48, 307-320.	1.0	6
209	Patients With Atypical Femur Fractures Have the Same Mortality as the Background Populationâ€”Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 488-490.	3.1	6
210	Prenatal exposure to vitamin D from fortified margarine and risk of fractures in late childhood: period and cohort results from 222 000 subjects in the D-TECT observational study. <i>British Journal of Nutrition</i> , 2017, 117, 872-881.	1.2	6
211	High calcium intake in men not women is associated with all-cause mortality risk: Melbourne Collaborative Cohort Study. <i>Archives of Osteoporosis</i> , 2018, 13, 101.	1.0	6
212	FRAX® in clinical practice. <i>Nature Reviews Rheumatology</i> , 2011, 7, 686-688.	3.5	5
213	Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids. <i>Osteoporosis International</i> , 2013, 24, 1891-1897.	1.3	5
214	Response to Letter to the Editor: â€œDevelopment and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndromeâ€” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 362-363.	1.8	5
215	Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. <i>Journal of Bone and Mineral Research</i> , 2021, 36, 2162-2176.	3.1	5
216	Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	1.4	5

#	ARTICLE	IF	CITATIONS
217	Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS). <i>Thrombosis and Haemostasis</i> , 2006, 95, 915-916.	1.8	4
218	The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. <i>Rhinology</i> , 2017, 55, 195-201.	0.7	4
219	The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes. <i>Calcified Tissue International</i> , 2020, 106, 88-93.	1.5	4
220	Osteoarthritis in osteogenesis imperfecta: A nationwide register-based cohort study. <i>Bone</i> , 2022, 154, 116222.	1.4	4
221	Standardization of BMD T-Scores in the First Five Years After the Menopause. <i>Journal of Clinical Densitometry</i> , 2003, 6, 87-95.	0.5	3
222	Prevention and treatment of osteoporosis in women: an update. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2009, 19, 157-163.	0.1	3
223	Bespoke or one size fits all? Vitamin D fortification, targeted supplementation in risk groups or individual measurement?. <i>Maturitas</i> , 2017, 103, 1-2.	1.0	3
224	Lactose avoidance and bone. <i>Maturitas</i> , 2018, 109, A1-A2.	1.0	3
225	Vitamin D supplementation for musculoskeletal health outcomes in adults – The end of the beginning?. <i>Maturitas</i> , 2019, 122, 87-88.	1.0	3
226	Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. <i>Health Technology Assessment</i> , 2021, 25, 1-106.	1.3	3
227	Fractures following pregnancy in Osteogenesis imperfecta – A self-controlled case series using Danish Health Registers. <i>Bone</i> , 2022, 154, 116177.	1.4	3
228	The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study. <i>BMC Endocrine Disorders</i> , 2022, 22, 14.	0.9	3
229	Regulation of bone mass in endocrine diseases including diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101614.	2.2	3
230	Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. <i>Osteoporosis International</i> , 2022, 33, 1579-1589.	1.3	3
231	Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study. <i>Osteoporosis International</i> , 2022, 33, 2155-2164.	1.3	3
232	Sequential osteoporosis treatment – the order of things. <i>Nature Reviews Endocrinology</i> , 2015, 11, 570-572.	4.3	2
233	The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old. <i>Journal of Internal Medicine</i> , 2017, 282, 560-562.	2.7	2
234	Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors. <i>European Geriatric Medicine</i> , 2017, 8, 408-412.	1.2	2

#	ARTICLE	IF	CITATIONS
235	The Changing Role of Patient Education in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 761-762.	3.1	2
236	Assessing Health Consequences of Vitamin D Fortification Utilizing a Societal Experiment Design: Methodological Lessons Learned from the D-Tect Project. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8136.	1.2	2
237	Age at first major osteoporotic fracture in Danes aged 50 and over: influence of diabetes on mean age at fracture and 1 year mortality. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
238	Population screening for fracture risk in postmenopausal women – a logical step in reducing the osteoporotic fracture burden?. <i>Osteoporosis International</i> , 0, , .	1.3	2
239	Estimates of fracture probability in Denmark: reply to Johansson et al. <i>Osteoporosis International</i> , 2007, 18, 1145-1146.	1.3	1
240	Performance of BMD-independent risk scores adapted from the WHI and FRAX(R) collaborations in prediction of 5-year risk of hip fracture: The Danish nurses cohort. <i>Bone</i> , 2009, 44, S397.	1.4	1
241	Bone freezing and bisphosphonates. <i>Maturitas</i> , 2011, 69, 1-2.	1.0	1
242	Comment on Tadrous et al.: Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. <i>Osteoporosis International</i> , 2014, 25, 2669-2669.	1.3	1
243	Hiding in plain sight – unreported osteoporotic vertebral fractures. <i>European Radiology</i> , 2020, 30, 4711-4712.	2.3	1
244	A comparison of fracture risk assessment tools. , 2021, , 1589-1609.		1
245	Does bisphosphonate treatment reduce the risk of future cancer?. <i>Chinese Clinical Oncology</i> , 2019, 8, S3-S3.	0.4	1
246	FREM predicts 10-year incident fracture risk independent of FRAX® probability: a registry-based cohort study. <i>Osteoporosis International</i> , 2022, , 1.	1.3	1
247	Osteoporosis epidemiology using international cohorts. <i>Current Opinion in Rheumatology</i> , 0, Publish Ahead of Print, .	2.0	1
248	Clinical importance of accuracy-error and reference values in DXA – a nationwide study. <i>Journal of Clinical Densitometry</i> , 2007, 10, S209.	0.5	0
249	Comment on Schott et al.: Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. <i>Osteoporosis International</i> , 2007, 18, 699-699.	1.3	0
250	FEV1 for identification of low BMD in patients with COPD. <i>Bone</i> , 2009, 44, S373-S374.	1.4	0
251	Time trends for alendronate prescription practices in patients with chronic pulmonary disease and patients exposed to systemic glucocorticoids. <i>Bone</i> , 2010, 47, S195.	1.4	0
252	Inverse Association Between Duration of Use of Acid-Suppressive Medications and Fracture Risk – Reply. <i>Archives of Internal Medicine</i> , 2011, 171, 1044.	4.3	0

#	ARTICLE	IF	CITATIONS
253	Essentials in rheumatology: disease management * 134. Metabolic bone diseases. Rheumatology, 2012, 51, iii7-iii13.	0.9	0
254	Characteristics of patients who suffer major osteoporotic fractures despite adhering to bisphosphonate treatment: A national prescription register study. Bone, 2012, 50, S58.	1.4	0
255	Bisphosphonates and colon cancer: reply. Osteoporosis International, 2013, 24, 1141-1142.	1.3	0
256	Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted. BMJ, The, 2013, 346, f1514-f1514.	3.0	0
257	Response: Is heart failure a debatable endâ€point for bisphosphonate treatment in an older osteoporotic population?. Journal of Internal Medicine, 2014, 275, 198-198.	2.7	0
258	Reply to: systematic review and metaâ€analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women. International Journal of Rheumatic Diseases, 2017, 20, 2144-2145.	0.9	0
259	Osteoporosis; Prevention and Caâ€ Vitamin D Treatment. , 2019, , 270-274.		0
260	Response to Shao Et Al.. Journal of Bone and Mineral Research, 2020, 36, 619-620.	3.1	0
261	Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A Danish national cohort study. Bone, 2021, 153, 116158.	1.4	0
262	Ten year absolute risk of osteoporotic fractures according to BMD T-score at menopause. The Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research, 2006, .	3.1	0
263	Risk factors for post peak bone loss and osteoporotic fracture: Lessons from population studies. , 2018, , 123-152.		0
264	OR13-03 Understanding Why Older People with Low Trauma Fractures Die Prematurely. Journal of the Endocrine Society, 2020, 4, .	0.1	0